AMR Accelerator Urges Investment in Antibiotic Development

Antibiotic resistance is a growing global health threat, and urgent action is needed to develop new treatments. The AMR Accelerator—a €479 million public-private partnership—calls for sustained investment to preserve Europe’s antibiotic research capacity and infrastructure.

The programme was created to accelerate the development of tools and treatments to fight drug-resistant bacteria and strengthen the scientific basis of AMR and TB research. Ninety-eight partners in nine different consortia have been working since 2019 to progress the development of new medicines to treat or prevent resistant bacterial infections.

The coordination and support across the programme are ensured by the COMBINE project (“Collaboration for prevention and treatment of MDR bacterial infections”). BIOCOM Interrelations GmbH is leading one of COMBINE’s key objectives: facilitating communication among AMR Accelerator partners, disseminating news and results, and increasing visibility and outreach to key stakeholders in the field.

Over the past five years, the AMR Accelerator has advanced 44 antibacterial programmes, including seven clinical trials. However, long-term funding is crucial to ensure these efforts result in life-saving antibiotics reaching patients.

Read more: https://amr-accelerator.eu/publications/